Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation
Cytomegalovirus (CMV) infection is common following allogeneic hematopoietic stem cell transplant (HSCT) and is a major cause of morbidity and increased mortality. Whilst pharmacotherapy can be effective in the prevention and treatment of CMV, these agents are often expensive, toxic and in some case...
Päätekijät: | , , , |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
Frontiers Media S.A.
2020-07-01
|
Sarja: | Frontiers in Immunology |
Aiheet: | |
Linkit: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01694/full |